Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
KAIO (KAIO) 24-hour volatility reaches 71.4%: TGE listing on multiple exchanges drives sharp fluctuations

KAIO (KAIO) 24-hour volatility reaches 71.4%: TGE listing on multiple exchanges drives sharp fluctuations

Bitget PulseBitget Pulse2026/05/07 22:02
Show original
By:Bitget Pulse

Volatility Overview

Over the past 24 hours, the price of KAIO surged from a low of $0.134186 to a high of $0.230, and is now at $0.142458—an amplitude of 71.4%. The 24-hour trading volume is around $24.74 million, down from its initial surge at listing but liquidity remains active.

Brief Analysis of Abnormal Fluctuations

• The TGE was launched on May 6, 2026, with spot trading going live simultaneously on multiple exchanges such as KuCoin, Bitget, and WEEX (for example, KAIO/USDT pair opened on KuCoin at UTC 13:00), causing the price to skyrocket from the bottom of $0.003 by over 5000%, reaching a peak of $0.300.

• As a cross-chain RWA tokenization protocol, the project has already onboarded five institutional funds, TVL has surpassed $100 million, and it has received $19M in funding from Tether, Laser Digital and others. Its product was deployed across more than ten chains prior to listing, bolstering market confidence.

Market Opinions and Outlook

The prevailing sentiment in the community is positive, positioning KAIO as a leading RWA infrastructure project and emphasizing “product-first, real TVL” (not speculative hype). In the short term, attention is on liquidity accumulation and the upcoming airdrop (starting May 8) following a pullback; in the long run, the potential for institutional funds on-chain is seen as promising. However, high volatility risks are also cautioned.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is provided for information reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23